ClinicalTrials.gg
CompletedNCT06504862Updated Jan 9, 2026Results posted

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

A Phase 1 interventional study of Zongertinib and Dabigatran-etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

For Part 1 of the trial, the main objective is to assess the effect of a single dose of zongertinib on the pharmacokinetics of a single dose of dabigatran-etexilate. For Part 2 of the trial, the main objective is to assess the effect of zongertinib at steady-state on the pharmacokinetics of a single dose of rosuvastatin, metformin and furosemide (administered as a cocktail).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 55 years (inclusive)
  • (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  • Signed and dated written in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria :

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Part 1: dabigatran-etexilate (R), then zongertinib and dabigatran-etexilate (T)

    Participants were administered a 150 milligram (mg) dabigatran-etexilate hard capsule orally with 240 milliliters (mL) of water after an overnight fast of at least 10 hours on Day 1 of period 1 (Reference treatment, R). After a wash-out period, participants were administered two 60 mg film-coated tablets of zongertinib (total dose: 120 mg) orally, and a 150 mg dabigatran-etexilate hard capsule orally on Day 1 of period 2 (Test treatment, T). Both medications were administered with 240 mL of water after an overnight fast of at least 10 hours.

    Drug: Zongertinib · Drug: Dabigatran-etexilate

  • Experimental
    Part 2: drug cocktail (R), then zongertinib and drug cocktail (T)

    Participants were administered a cocktail consisting of a 10 mg rosuvastatin film-coated tablet, a 10 mg metformin oral solution, and a 1 mg furosemide oral solution with 240 mL of water after an overnight fast of at least 10 hours on Day 1 of period 1 (Reference treatment, R). In period 2, from Day -9 to Day 3, participants were administered two 60 mg film-coated tablets of zongertinib (total dose: 120 mg) orally every day. On Day 1, participants were also administered a cocktail consisting of a 10 mg rosuvastatin film-coated tablet, a 10 mg metformin oral solution, and a 1 mg furosemide oral solution (Test treatment, T). Every medication was administered with 240 mL of water after an overnight fast of at least 10 hours.

    Drug: Zongertinib · Drug: Rosuvastatin · Drug: Metformin hydrochloride · Drug: Furosemide

Interventions

  • A 120 mg dose on Day 1 of period 2 (Part 1) OR daily (Part 2) with 240 mL of water after an overnight fast of at least 10 hours.

    Also known as: Hernexeos®

  • A 150 mg dose on Day 1 of each period with 240 mL of water after an overnight fast of at least 10 hours.

    Also known as: Pradaxa®

  • A 10 mg dose on Day 1 of each period with 240 mL of water after an overnight fast of at least 10 hours.

    Also known as: Crestor®

  • A 10 mg dose on Day 1 of each period with 240 mL of water after an overnight fast of at least 10 hours.

    Also known as: MetfoLiquid GeriaSan®

  • A 1 mg dose on Day 1 of each period with 240 mL of water after an overnight fast of at least 10 hours.

    Also known as: Lasix®

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of dabigatran in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 hours (h) before dabigatran-etexilate administration (R only), within 3 h prior to zongertinib administration (T only), and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 34, 48 h after dabigatran-etexilate administration (R and T).

  2. Part 1: Maximum Measured Concentration of Dabigatran in Plasma (Cmax)

    Maximum measured concentration of dabigatran in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 hours (h) before dabigatran-etexilate administration (R only), within 3 h prior to zongertinib administration (T only), and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 34, 48 h after dabigatran-etexilate administration (R and T).

  3. Part 2: Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

  4. Part 2: Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax)

    Maximum measured concentration of rosuvastatin in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

  5. Part 2: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

  6. Part 2: Maximum Measured Concentration of Metforminin in Plasma (Cmax)

    Maximum measured concentration of metforminin in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

  7. Part 2: Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of furosemide in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

  8. Part 2: Maximum Measured Concentration of Furosemide in Plasma (Cmax)

    Maximum measured concentration of furosemide in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

Secondary outcomes

  1. Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of dabigatran in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 hours (h) before dabigatran-etexilate administration (R only), within 3 h prior to zongertinib administration (T only), and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 34, 48 h after dabigatran-etexilate administration (R and T).

  2. Part 2: Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

  3. Part 2: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

  4. Part 2: Area Under the Concentration-time Curve of Furosemide in in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of furosemide in in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

    Time frame: Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).

07

Results

Posted Jan 9, 2026

Participant flow

This was a non-randomised, open-label, 2-period fixed-sequence crossover trial in healthy male participants to compare the test treatments (T: zongertinib and dabigatran-etexilate in part 1; zongertinib, rosuvastatin, metformin, furosemide in part 2) to the reference treatments (R: dabigatran-etexilate in part 1; rosuvastatin, metformin, furosemide in part 2).

Period 1, reference treatment (R)
Participant flow — Period 1, reference treatment (R)
MilestonePart 1: Dabigatran-etexilate (R), Then Zongertinib and Dabigatran-etexilate (T)Part 2: Drug Cocktail (R), Then Zongertinib and Drug Cocktail (T)
Started1616
Completed1616
Not completed00
Transition period
Participant flow — Transition period
MilestonePart 1: Dabigatran-etexilate (R), Then Zongertinib and Dabigatran-etexilate (T)Part 2: Drug Cocktail (R), Then Zongertinib and Drug Cocktail (T)
Started1616
Completed1516
Not completed10
Withdrew: Adverse event10
Period 2, test treatment (T)
Participant flow — Period 2, test treatment (T)
MilestonePart 1: Dabigatran-etexilate (R), Then Zongertinib and Dabigatran-etexilate (T)Part 2: Drug Cocktail (R), Then Zongertinib and Drug Cocktail (T)
Started1516
Completed1516
Not completed00

Outcome measures

PrimaryPart 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of dabigatran in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 hours (h) before dabigatran-etexilate administration (R only), within 3 h prior to zongertinib administration (T only), and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 34, 48 h after dabigatran-etexilate administration (R and T).
Reported as:
Geometric least squares mean · hour*nanogram/milliliter (h*ng/mL)
Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanogram/milliliter (h*ng/mL)Dabigatran-etexilate (R)Zongertinib and dabigatran-etexilate (T)
Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)725.25 ± NA971.67 ± NA
Statistical analysis
  • Dabigatran-etexilate (R) vs Zongertinib and dabigatran-etexilate (T) · Ratio of adjusted geometric means [%]: 133.98 · 90% CI 105.52 to 170.11Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 39.0
PrimaryPart 1: Maximum Measured Concentration of Dabigatran in Plasma (Cmax)

Maximum measured concentration of dabigatran in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 hours (h) before dabigatran-etexilate administration (R only), within 3 h prior to zongertinib administration (T only), and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 34, 48 h after dabigatran-etexilate administration (R and T).
Reported as:
Geometric least squares mean · nanogram/milliliter (ng/mL)
Part 1: Maximum Measured Concentration of Dabigatran in Plasma (Cmax)
nanogram/milliliter (ng/mL)Dabigatran-etexilate (R)Zongertinib and dabigatran-etexilate (T)
Part 1: Maximum Measured Concentration of Dabigatran in Plasma (Cmax)89.01 ± NA110.53 ± NA
Statistical analysis
  • Dabigatran-etexilate (R) vs Zongertinib and dabigatran-etexilate (T) · Ratio of adjusted geometric means [%]: 124.19 · 90% CI 96.13 to 160.43Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 42.0
PrimaryPart 2: Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · hour*nanomole/liter (h*nmol/L)
Part 2: Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomole/liter (h*nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)102.98 ± NA237.15 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 230.30 · 90% CI 195.68 to 271.04Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 26.7
PrimaryPart 2: Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax)

Maximum measured concentration of rosuvastatin in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · nanomole/liter (nmol/L)
Part 2: Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax)
nanomole/liter (nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax)8.87 ± NA26.75 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 301.68 · 90% CI 247.19 to 368.19Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 33.0
PrimaryPart 2: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · hour*nanomole/liter (h*nmol/L)
Part 2: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomole/liter (h*nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)1355.69 ± NA1125.52 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 83.02 · 90% CI 76.48 to 90.12Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 13.3
PrimaryPart 2: Maximum Measured Concentration of Metforminin in Plasma (Cmax)

Maximum measured concentration of metforminin in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · nanomole/liter (nmol/L)
Part 2: Maximum Measured Concentration of Metforminin in Plasma (Cmax)
nanomole/liter (nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Maximum Measured Concentration of Metforminin in Plasma (Cmax)230.25 ± NA174.00 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 75.57 · 90% CI 68.03 to 83.95Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 17.1
PrimaryPart 2: Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of furosemide in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · hour*nanomole/liter (h*nmol/L)
Part 2: Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomole/liter (h*nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)172.84 ± NA238.43 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 137.95 · 90% CI 120.17 to 158.36Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 22.5
PrimaryPart 2: Maximum Measured Concentration of Furosemide in Plasma (Cmax)

Maximum measured concentration of furosemide in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · nanomole/liter (nmol/L)
Part 2: Maximum Measured Concentration of Furosemide in Plasma (Cmax)
nanomole/liter (nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Maximum Measured Concentration of Furosemide in Plasma (Cmax)75.73 ± NA113.45 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 149.80 · 90% CI 116.12 to 193.25Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 44.4
SecondaryPart 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of dabigatran in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 hours (h) before dabigatran-etexilate administration (R only), within 3 h prior to zongertinib administration (T only), and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 34, 48 h after dabigatran-etexilate administration (R and T).
Reported as:
Geometric least squares mean · hour*nanogram/milliliter (h*ng/mL)
Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanogram/milliliter (h*ng/mL)Dabigatran-etexilate (R)Zongertinib and dabigatran-etexilate (T)
Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)700.45 ± NA942.02 ± NA
Statistical analysis
  • Dabigatran-etexilate (R) vs Zongertinib and dabigatran-etexilate (T) · Ratio of adjusted geometric means [%]: 134.49 · 90% CI 105.56 to 171.34Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 39.5
SecondaryPart 2: Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · hour*nanomole/liter (h*nmol/L)
Part 2: Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanomole/liter (h*nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)93.10 ± NA231.53 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 248.69 · 90% CI 211.03 to 293.07Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 27.0
SecondaryPart 2: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · hour*nanomole/liter (h*nmol/L)
Part 2: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanomole/liter (h*nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)1343.93 ± NA1113.21 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 82.83 · 90% CI 76.27 to 89.96Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 13.4
SecondaryPart 2: Area Under the Concentration-time Curve of Furosemide in in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of furosemide in in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: participant (considered as random) and treatment (considered as fixed). These quantities were then back-transformed to the original scale.

Time frame:
Within 3 h prior to drug cocktail administration (R), within 15 minutes prior to drug cocktail and zongertinib administration (T), and 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h after drug cocktail administration (R and T).
Reported as:
Geometric least squares mean · hour*nanomole/liter (h*nmol/L)
Part 2: Area Under the Concentration-time Curve of Furosemide in in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanomole/liter (h*nmol/L)Drug cocktail (R)Zongertinib and drug cocktail (T)
Part 2: Area Under the Concentration-time Curve of Furosemide in in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)164.01 ± NA235.33 ± NA
Statistical analysis
  • Drug cocktail (R) vs Zongertinib and drug cocktail (T) · Ratio of adjusted geometric means [%]: 143.49 · 90% CI 123.78 to 166.33Ratio \[%\] = (adjusted geometric mean T/adjusted geometric mean R)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 24.2

Adverse events

Collected over All adverse events occurring after 1st drug administration within treatment-specific time frames after end of administration, OR until next treatment administration, were assigned to treatment. The time frames for each treatment are: 3 days (dabigatran-etexilate), 6 days (cocktail), 14 days (zongertinib, zongertinib and dabigatran-etexilate, zongertinib and cocktail). All-cause mortality time frame: from drug administration until end of study, up to 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Dabigatran-etexilate (R)0/16 (0%)0/16 (0%)2/16 (12.5%)
Part 1: Zongertinib0/15 (0%)0/15 (0%)0/15 (0%)
Part 1: Zongertinib and Dabigatran-etexilate (T)0/15 (0%)0/15 (0%)3/15 (20%)
Part 2: Drug Cocktail (R)0/16 (0%)0/16 (0%)5/16 (31.3%)
Part 2: Zongertinib0/16 (0%)0/16 (0%)9/16 (56.3%)
Part 2: Zongertinib and Drug Cocktail (T)0/16 (0%)0/16 (0%)5/16 (31.3%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPart 1: Dabigatran-etexilate (R)Part 1: ZongertinibPart 1: Zongertinib and Dabigatran-etexilate (T)Part 2: Drug Cocktail (R)Part 2: ZongertinibPart 2: Zongertinib and Drug Cocktail (T)
Abdominal painGastrointestinal disorders0/160/150/150/163/160/16
HeadacheNervous system disorders0/160/150/152/161/163/16
DiarrhoeaGastrointestinal disorders0/160/151/150/162/160/16
Dermatitis acneiformSkin and subcutaneous tissue disorders0/160/150/150/162/160/16
DizzinessNervous system disorders0/160/151/150/160/160/16
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/160/151/150/161/160/16
HaematomaVascular disorders1/160/151/150/160/160/16
VertigoEar and labyrinth disorders0/160/150/151/160/160/16
Conjunctival haemorrhageEye disorders0/160/150/151/160/160/16
FlatulenceGastrointestinal disorders0/160/150/150/160/161/16

Baseline characteristics

Treated set (TS): all participants who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)Part 1: Dabigatran-etexilate (R), Then Zongertinib and Dabigatran-etexilate (T)Part 2: Drug Cocktail (R), Then Zongertinib and Drug Cocktail (T)Total
Mean35.9 ± 9.437.8 ± 11.236.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Dabigatran-etexilate (R), Then Zongertinib and Dabigatran-etexilate (T)Part 2: Drug Cocktail (R), Then Zongertinib and Drug Cocktail (T)Total
Female000
Male161632
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Dabigatran-etexilate (R), Then Zongertinib and Dabigatran-etexilate (T)Part 2: Drug Cocktail (R), Then Zongertinib and Drug Cocktail (T)Total
Hispanic or Latino000
Not Hispanic or Latino161632
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Dabigatran-etexilate (R), Then Zongertinib and Dabigatran-etexilate (T)Part 2: Drug Cocktail (R), Then Zongertinib and Drug Cocktail (T)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White151530
More than one race011
Unknown or Not Reported000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Oct 2024, 1 month.

Results were first posted in Jan 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Jul 17, 2024
StartActual
Aug 20, 2024
Primary completionActual
Oct 3, 2024
CompletionActual
Dec 18, 2024
Results first posted
Jan 9, 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06504862
Responsible party
Sponsor
First posted
Jul 17, 2024
Start date
Aug 20, 2024
Primary completion
Oct 3, 2024
Completion
Dec 18, 2024
Results posted
Jan 9, 2026
Last update
Jan 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zongertinib · Furosemide

Start the discussion